



Bueno De Paiva, L., Bernusso, V. A., Machado-Neto, J. A., Traina, F., Ridley, A., Olalla-Saad, S. T., & Lazarini, M. (2018). Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation. *Small GTPases*.  
<https://doi.org/10.1080/21541248.2018.1546098>

Peer reviewed version

Link to published version (if available):  
[10.1080/21541248.2018.1546098](https://doi.org/10.1080/21541248.2018.1546098)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Taylor & Francis at <https://doi.org/10.1080/21541248.2018.1546098> . Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

## ***Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation***

Luciana Bueno de Paiva<sup>1</sup>, Vanessa Aline Bernusso<sup>1</sup>, João Agostinho Machado-Neto<sup>2,3</sup>  
Fabiola Traina<sup>2</sup>, Anne J Ridley<sup>4,5</sup>, Sara Teresinha Olalla Saad<sup>1</sup>, Mariana Lazarini<sup>1,6</sup>.

(1) Hematology and Blood Transfusion Center, University of Campinas, Campinas, São Paulo, Brazil

(2) Department of Internal Medicine, University of São Paulo at Ribeirão Preto Medical School, Ribeirão Preto, São Paulo, Brazil

(3) Department of Pharmacology, Institute of Biomedical Sciences of the University of São Paulo, São Paulo, Brazil

(4) Randall Centre of Cell & Molecular Biophysics, King's College London, London, United Kingdom

(5) School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK

(6) Department of Pharmaceutical Sciences - Federal University of São Paulo, Diadema, São Paulo, Brazil

Corresponding Author:

Mariana Lazarini, PhD and Sara T. Olalla Saad

Institute of Environmental, Chemical and Pharmaceutical Sciences

Department of Pharmaceutical Sciences

Federal University of São Paulo

Rua São Nicolau, 210, CEP 09913-030

Diadema, SP, Brazil

Phone: 55-11-40440500

E-mail: lazarini@unifesp.br

**Key words:** prostate cancer, glutamine, PC3 cells, LNCaP cells, RhoA, RhoC, Rho GTPases

**Word count:** 3118

**Running title:** RhoA and RhoC in glutamine deprivation response

## Abstract

RhoA and RhoC contribute to the regulation of glutamine metabolism, which is a crucial determinant of cell growth in some types of cancer. Here we investigated the participation of RhoA and RhoC in the response of prostate cancer cells to glutamine deprivation. We found that RhoA and RhoC activities were up- or downregulated by glutamine reduction in PC3 and LNCaP cells, which was concomitant to a reduction in cell number and proliferation. Stable overexpression of wild type RhoA or RhoC did not alter the sensitivity to glutamine deprivation. However, PC3 cells expressing dominant negative RhoA<sup>N19</sup> or RhoC<sup>N19</sup> mutants were more resistant to glutamine deprivation. Our results indicate that RhoA and RhoC activities could affect cancer treatments targeting the glutamine pathway.

## Introduction

In cancer cells, a substantial amount of energy is produced by aerobic glycolysis and most of the incoming glucose is converted to lactate (Warburg effect) <sup>1</sup>. The lower rates of ATP generated by aerobic glycolysis are partially compensated by glutaminolysis. In this process, glutamine is converted to glutamate by glutaminase and further metabolized to  $\alpha$ -ketoglutarate, which feeds into the tricarboxylic acid (TCA) cycle <sup>2</sup>. Glutamine also participates in the prevention of oxidative damage, and in the biosynthesis of nonessential amino acids, nucleotide and fatty acids <sup>3</sup>. Therefore, many tumor cells rely on glutamine to maximize their growth <sup>4</sup> and targeting the glutamine pathway is considered a promising strategy for treating cancer.

RhoA and RhoC are highly homologous GTPases (approximately 92% amino acid identity) that have each been implicated in glutamine metabolism <sup>5-7</sup>. RhoA has been better characterized than RhoC, however several studies have demonstrated that they present distinct functions in cancer. RhoA is frequently involved in cell cycle progression and migration, whereas RhoC is linked to metastasis and reduced cell survival <sup>8,9</sup>.

RhoA inhibition in an epithelial mammalian cell model was synthetic lethal with Myc, a master regulator of glutamine metabolism <sup>7</sup>. Inhibition of RhoA induced apoptosis in Myc-transformed cells, which was reversed by exogenous  $\alpha$ -ketoglutarate treatment. In addition, Myc was unable to elevate glutamate levels when the Rho subfamily was inhibited with C3 transferase Rho inhibitor, suggesting that Myc is

dependent on the signaling mediated by Rho to supply the glutamine demands of transformation <sup>7</sup>. In NIH3T3 cells, the pharmacological inhibition of a specific splice variant of mitochondrial glutaminase (GLS1) was capable of reversing the transformation caused by the RhoGEF Dbl oncogenic protein <sup>5</sup>. Dbl has been shown to activate several Rho GTPases, including RhoA <sup>10</sup>. The colony forming ability of NIH3T3 cells transformed by overexpression of RhoC, Rac1 or Cdc42 was also blocked by GLS1 knockdown, indicating that inactivation of glutaminolysis was sufficient to prevent Rho GTPase-induced transformation <sup>5</sup>. Silencing of RhoC in inflammatory breast cancer cells markedly decreased glutamine uptake, without altering glucose uptake or lactate production. Regardless of the lower glutamine uptake, the cells remained dependent on glutamine. RhoC knockdown also increased glutamine synthetase, but did not alter GLS1 <sup>6</sup>.

Despite these recent studies, the relative contributions of RhoA and RhoC in glutamine metabolism remain unclear. Here, we compare the roles of both proteins in glutamine dependency of prostate cancer cells by evaluating the effects of RhoA or RhoC activation and inactivation on the survival of prostate cancer cell lines cultured under glutamine deprivation.

## Results

To measure the sensitivity of prostate cancer cells to glutamine deprivation, we evaluated the MTT staining (which measures cell metabolic activity and reflects in part the number of viable cells), number, proliferation, cell cycle, apoptosis and autophagy of PC3 and LNCaP cell lines cultured under different concentrations of glutamine for 72 hours. MTT staining of both cell lines was gradually reduced with decreasing glutamine, showing an approximately 40% decrease in the complete absence of glutamine ( $p < 0.05$ ) (Figure 1A-B). Glucose deprivation in the presence of normal glutamine concentration (300 mg/L) also decreased MTT staining (Figure 1C-D), indicating that glutamine is necessary though insufficient to maintain high cellular metabolic rates. PC3 and LNCaP cell number and relative proliferation decreased when cultured under an intermediate concentration (37.5 mg/mL) or absence of glutamine (Figure 1E-H). PC3 cell cycle is not statistically changed by the reduction or absence of glutamine (Figure 1I). In LNCaP cells, glutamine reduction induced an accumulation in S and G<sub>2</sub>/M cell cycle phases, whereas the complete absence of glutamine decreased the

percentage of cells in G<sub>2</sub>/M phases (Figure 1J). Surprisingly, a significant protective effect on apoptosis was observed by reduction or absence of glutamine in LNCaP cells but not PC3 cells (Figure 1K-L). Autophagy was not induced by glutamine reduction in either PC3 or LNCaP cells, as indicated by the ratio of LC3II/I (Figure M-N).

We next sought to investigate the activities of RhoA and RhoC in prostate cancer cells cultured under glutamine deprivation. PC3 cells cultured under reduction or absence of glutamine showed a trend of increase in RhoA and RhoC activities, compared to normal glutamine concentration (Figure 2A-B). In LNCaP cells, RhoA and RhoC activity showed a trend of a biphasic response to glutamine levels: it was increased at the intermediate dose and slightly reduced in the absence of glutamine when compared to normal glutamine concentration (Figure 2C-D).

We then investigated the effects of RhoA and RhoC on glutamine dependency by stably expressing GFP-tagged wild type and dominant negative mutants of RhoA (RhoA<sup>N19</sup>) and RhoC (RhoC<sup>N19</sup>) in PC3 cells. Transfection efficiency was confirmed by GFP detection using flow cytometry (Figure 3A) and western blotting (Figure 3B-C). More than 60% of GFP positive cells were obtained in all conditions, with the exception of RhoC<sup>wt</sup> expression, which resulted in a strong reduction in cell proliferation and consequent low transfection efficiency with approximately 10% of GFP-positive cells after sorting (Figure 3A). Cell morphology was visualized by fluorescence microscopy to detect GFP (Figure 3D) and cell area and circularity were analyzed. RhoA<sup>wt</sup> [median 405 (range 134 – 1757  $\mu\text{m}^2$ )], RhoA<sup>N19</sup> [788 (164 – 1907  $\mu\text{m}^2$ )], RhoC<sup>wt</sup> [930 (291 – 1652  $\mu\text{m}^2$ )] and RhoC<sup>N19</sup> [547 (198 – 2104  $\mu\text{m}^2$ )] expressing cells had decreased cell area in comparison with control cells (empty vector) [1072 (269 – 3365  $\mu\text{m}^2$ )], all  $P < 0.05$  (Figure 3E). Circularity was decreased in RhoA<sup>N19</sup> [median 0.36 (range 0.06 – 0.94)] and increased in RhoC<sup>N19</sup> [0.72 (0.32 – 0.93)] expressing cells, compared to control [0.52 (0.12 – 0.84)], all  $P < 0.05$  (Figure 3F); ANOVA with Dunnett's post-test. It was not possible to study the responses of RhoC<sup>wt</sup>-expressing cells to glutamine deprivation due to the low transfection efficiency (data not shown). Expression of RhoA<sup>wt</sup> and RhoA<sup>N19</sup> decreased MTT cell labelling under normal glutamine concentration (300 mg/L). PC3 cells expressing RhoA<sup>wt</sup> were still sensitive to glutamine deprivation (Figure 3G). Conversely, PC3 cells expressing RhoA<sup>N19</sup> or RhoC<sup>N19</sup> were more resistant to glutamine deprivation, since their MTT labelling was not significantly affected by glutamine

withdrawal (Figure 3G-H). Apoptosis was not significantly altered by RhoA<sup>wt</sup>, RhoA<sup>N19</sup> or RhoC<sup>N19</sup> in any of the tested conditions (Figure 3I-J).

## Discussion

Reliance on glutamine varies substantially between different cancer cells. Some types of cells are highly sensitive to glutamine deprivation, while others do not require an exogenous source of this amino acid to survive<sup>4</sup>. Here we show that PC3 and LNCaP prostate cancer cells respond to glutamine reduction or deprivation mainly by decreased cell proliferation. However, the effects of glutamine deprivation on the cell cycle and apoptosis varied between these cell lines. PC3 and LNCaP cells were established from very different prostate tumors<sup>11, 12</sup> and diverge in their metastatic potential, gene expression profile and metabolism control<sup>13, 14</sup>. Therefore, our data are in accordance with other studies that showed that glutamine sensitivity is related to aggressiveness<sup>15</sup>, modulation of glucose metabolism and the status of other genes<sup>16</sup>.

It is interesting that PC3 cells and LNCaP cells show different patterns of RhoA/RhoC activity depending on glutamine levels. Whereas both RhoA and RhoC activity increased in PC3 cells in response to glutamine reduction or deprivation, in LNCaP cells, RhoA and RhoC activity was increased only under glutamine reduction but not deprivation. Rho GTPases play a part in G<sub>1</sub> progression in many cell types<sup>17</sup> and the biphasic response in RhoA/RhoC activity is similar to the decrease in G<sub>1</sub> cell cycle phase in LNCaP cells cultured in reduced glutamine levels. Thus, it is possible that increased RhoA/RhoC activity stimulates G<sub>1</sub>/S phase transition in these cells. In addition, our previous study showed that PC3 cells are more responsive to the alteration of RhoA and RhoC pathways compared to LNCaP cells<sup>18</sup>, which may also explain the difference induced by glutamine deprivation in RhoA/C activities between the cell lines.

Stable overexpression of wild type or dominant negative mutants of RhoA or RhoC produced substantial alterations in the morphology and MTT staining of PC3 cells even in normal glutamine concentration. Cell circularity was increased by RhoA<sup>N19</sup> and decreased by RhoC<sup>N19</sup>, highlighting the different functions of these two highly homologous proteins. Distinct effects of RhoA and RhoC have been previously described in the morphology of prostate cancer cells<sup>9, 19</sup>. In addition, RhoC<sup>wt</sup> effects on the reduction of MTT staining were stronger than RhoA<sup>wt</sup>. RhoA or RhoC have been described to increase cell growth<sup>18, 20, 21</sup>. However, their stable overexpression may also

lead to a decrease in cell growth caused by the profound changes in the cytoskeleton <sup>22</sup>, <sup>23</sup>, which is accordance with our results.

RhoA and RhoC can have both pro- and anti-oncogenic activities depending on the context <sup>24-26</sup>. In addition, RhoA gain and loss-of-function mutations have been identified in cancer patients <sup>27, 28</sup>. We observed that dominant negative mutant forms of RhoA or RhoC prevented the decrease in MTT staining induced by glutamine deprivation, implying that RhoA and RhoC promote growth inhibition under these conditions. Inflammatory breast cancer cells depleted for RhoC presented decreased glutamine uptake, but remained dependent on glutamine <sup>6</sup>. However, this is the first time that RhoA<sup>N19</sup> and RhoC<sup>N19</sup> effects on glutamine sensitivity are evaluated. All together, these results indicate that determining RhoA/C activity in cancer cells is relevant when considering targeting the glutamine pathway therapeutically.

Further studies are important to elucidate the roles of RhoA and RhoC in glutamine metabolism. Our findings add new insights regarding the participation of these two proteins in the sensitivity of prostate cancer cells to glutamine deprivation.

## **Materials and Methods**

### *Cell culture*

The human prostate cancer cell lines LNCaP and PC3 were acquired from ATCC (American Type Culture Collection, Philadelphia, USA). Cells were cultured in RPMI medium (Gibco) with 10% FBS and maintained in a humidified incubator at 37°C and 5% CO<sub>2</sub>. To evaluate the cellular response to glutamine deprivation, cells were grown in culture medium containing 10% FBS and different glutamine concentrations.

### *MTT assays and determining cell number*

For Methylthiazoletetrazolium (MTT; 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) (Sigma) staining, 9×10<sup>3</sup> cells per well were cultured in 96-well plates in RPMI with 10% FBS for 72 hours. After this period, 10 µL of 5 mg/mL MTT solution were added to each well and the cells were incubated at 37°C for 4 hours. The reaction was stopped by addition of 100 µl of 0.1 N HCl in isopropanol and the optical densities were measured with a spectrophotometer at 595 nm absorbance. Cell number was calculated by counting the cells cultured under different conditions using a Neubauer chamber.

### *CFSE cell labelling*

Cell proliferation was evaluated by CellTrace™ CFSE Cell Proliferation Kit Protocol (Thermofisher) according manufacture instructions. In brief,  $2 \times 10^5$  cells were staining with 5  $\mu$ M carboxyfluorescein diacetate, succinimidyl ester (CFSE) for 20 minutes in a 37°C water bath, washed and returned cell culture in the presence or absence glutamine. After 0 (initial time) and 72 (proliferation time) hours, CFSE fluorescence intensity analyzed in a FACSCalibur (BD Biosciences). The proliferation indexes were determined using the ModFit Software (BD Biosciences). Ten thousand events were acquired for each sample.

### *Cell cycle analysis*

Cell cycle was evaluated by flow cytometry, as previously described <sup>29</sup>. Briefly, the cells were collected, fixed in 70% ethanol and stored at 4°C for at least 4 hours. After washing in PBS, the samples were suspended in cell cycle buffer (0.1% Triton X-100, 10 mg/mL propidium iodide, 0.1 mg/mL RNase A) and incubated at 37°C for 30 minutes. Fluorescence was detected with a FACSCalibur (BD Biosciences) and ModFit Software (BD Biosciences) was used to determine the proportions of cells in each cell cycle phase. Ten thousand events were acquired for each sample.

### *Rho GTPase activity assays*

RhoA, Cdc42 and RhoC activities were determined by affinity precipitation assay, as previously described <sup>18</sup>. Briefly, cell lysates (25mM Hepes, pH 7.5, 150mM NaCl, 1% Nonidet P-40, 10mM MgCl<sub>2</sub>, 1mM EDTA, 25mM NaF, 1mM Na<sub>3</sub>VO<sub>4</sub>, 10 $\mu$ g/mL aprotinin, 100 $\mu$ M PMSF, and 10% glycerol) were incubated with the GST-RBD at 4°C with rotation for 4 hours. After four washes, the pull down samples and total protein extracts were subjected to SDS-PAGE and western blotting analysis with specific antibodies.

### *Western blotting*

Cells were lysed with protein extraction buffer containing 100 mM Tris (pH 7.6), 1% Triton X-100, 150 mM NaCl, 0.1 mg Aprotinin, PMSF, 35 mg/mL, 10 mM Na<sub>3</sub>VO<sub>4</sub>, 100 mM NaF, 10 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and 4 mM EDTA. The protein extracts were subjected to SDS-PAGE and western blotting analysis with specific primary antibodies: anti-LC3



(ab128025) from abcam, Anti-RhoA (2117S) and anti-RhoC (3430S) from Cell Signaling Technology and anti-GFP (sc-9996) from Santa Cruz Technologies. The ECLTM Western Blotting Analysis System kit (Amersham Pharmacia Biotech) was used for developing. Anti-actin (sc-1616) or anti-GAPDH (sc-32233) from Santa Cruz Biotechnology were used as loading control and band quantification was performed with UN-SCAN-IT gel densitometry software.

#### *Stable transfection*

GFP-fusions of wild type forms of RhoA (RhoA<sup>wt</sup>) and RhoC (RhoC<sup>wt</sup>) and dominant negative mutants of RhoA (RhoA<sup>N19</sup>) and RhoC (RhoC<sup>N19</sup>) (in EGFP) were transfected into PC3 cells. Briefly, the cells were transfected using jetPEI (Polyplus transfection), according to the manufacturer's instructions. Cells expressing eGFP were used as control cells. Cells were then selected with 700µg/mL G418 (geneticin) for at least ten days then sorted for GFP using a FACSAria Fusion (Becton–Dickinson Biosciences).

#### *Analysis of cellular morphology*

Cell morphology was observed by fluorescence microscope through GFP detection. Image J software (National Institutes of Health) was used to measure the cell area and circularity. Circularity was calculated as previously described<sup>30</sup> and values ranged from 0.0 to 1.0, where a value of 1.0 designates a perfect circular shape and a value of 0.0 indicates an elongated polygon. At least 30 cells were analyzed for each condition.

#### *Assessment of apoptosis*

Apoptosis was determined with Annexin V Apoptosis Detection Kit (BD Biosciences), according to the manufacturer's instructions. All specimens were analyzed by a FACSCalibur (BD Biosciences) and at least ten thousand events were acquired for each sample.

#### *Statistical analysis*

Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). For comparisons, ANOVA test and Dunnett's post-test were used. A *P* value <0.05 was considered as statistically significant.

## Figure Legends

**Figure 1. Effects of glutamine reduction on prostate cancer cell MTT staining, cell number, CFSE cell labelling, cell cycle, apoptosis and autophagy.** PC3 and LNCaP cells were cultured for 72 hours under the indicated glutamine concentrations. (A-B) PC3 and LNCaP cell growth are decreased by reduced glutamine in the presence of glucose and (C-D) by reduced glucose in the presence of glutamine. (E-H) Decreased LNCaP and PC3 cell number and proliferation under reduced glutamine conditions. (I) PC3 cell cycle is not statistically changed by the reduction or absence of glutamine. (J) In LNCaP cells, reduced glutamine induces an accumulation in the S and G<sub>2</sub>-M phases of the cell cycle, whereas the absence of glutamine leads to the reduction of G<sub>2</sub>/M phases of the cell cycle. (K-L) The percentage of annexin V-positive cells was decreased upon glutamine reduction in LNCaP cells, but not in PC3 cells. (M-N) Glutamine reduction did not alter the ratio of LC-3II/LC3I in PC3 and LNCaP cells. Actin (42 kDa) was used to determine sample loading; the antibodies used for immunoblotting (IB) are indicated. Densitometry was performed and the ratio of target protein versus actin compared with the normalized value of control is shown. Analysis of variance (ANOVA) followed by a Dunnett's test was used to determine significance. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . NS = not significant. Data shown are presented as mean  $\pm$  standard deviation from at least four independent experiments.

**Figure 2. Effects of glutamine reduction on the activities of RhoA and RhoC in PC3 and LNCaP cells.** (A-B) RhoA and RhoC activities trend to increase by glutamine reduction or deprivation in PC3 cells. (C-D) LNCaP cells cultured under the intermediate glutamine concentration (37.5 mg/L) presented a trend of increase in RhoA and RhoC activities, whereas a trend of decrease in RhoA and RhoC activities was observed upon glutamine deprivation. (Upper panel) RhoA and RhoC activities were determined by pool down assays; actin (42 kDa) or GAPDH (37 kDa) were used to determine sample loading; the antibodies used for immunoblotting (IB) are indicated. (Lower panel) Bar graphs represent relative densitometry ratios of RhoA-GTP/RhoA (total) and RhoC-GTP/RhoC (total) of at least three independent experiments.

**Figure 3. Effects of the overexpression of wild type and dominant negative mutant RhoA/C in PC3 and LNCaP cells cultured under graded reduction of glutamine.**

(A) PC3 cells were stably transfected with wild type (RhoA<sup>wt</sup> or RhoC<sup>wt</sup>) and dominant negative mutant RhoA/C (RhoA<sup>N19</sup> or RhoC<sup>N19</sup>) fused to green fluorescent protein (GFP) and transfection efficiency was evaluated by flow cytometry. PC3 cells expressing eGFP were used as a control. (B-C) Transfection efficiency was also assessed by western blotting using anti-RhoA, anti-RhoC (upper blots) and anti-GFP antibodies (middle blots). Actin (42 kDa) or GAPDH (36 kDa) were used to determine sample loading. (D) Morphology of PC3 cells expressing RhoA<sup>wt</sup>, RhoC<sup>wt</sup>, RhoA<sup>N19</sup> and RhoC<sup>N19</sup> was observed by fluorescence microscopy through GFP detection. Scale bar = 50µm. (E-F) Area and circularity of PC3 cells were quantified with Image J Software. ANOVA followed by a Dunnett's test was used to determine significance. \*P<0.05, \*\*\*P<0.01. (G-H) Relative MTT staining of PC3 cells expressing RhoA<sup>wt</sup>, RhoA<sup>N19</sup> and RhoC<sup>N19</sup>. Expression of RhoA<sup>wt</sup> and RhoA<sup>N19</sup> decreased MTT staining under normal glutamine concentration (300mg/L) (both \*\*\*P≤0.001). Glutamine deprivation decreases the MTT staining in control cells (empty vector) and in RhoA<sup>wt</sup> expressing cells (###P≤0.001), but not in RhoA<sup>N19</sup> or RhoC<sup>N19</sup> expressing cells (NS=not significant). (I-J) Expression of RhoA<sup>wt</sup>, RhoA<sup>N19</sup> and RhoC<sup>N19</sup> did not alter the apoptosis of PC3 cells cultured in the presence or absence of glutamine. ANOVA followed by a Bonferroni test was used to determine significance.

### **Disclosure of interest**

The authors report no conflicts of interest.

### **Acknowledgments**

The authors would like to thank Tereza Salles, Fernanda Soares Nieamann and Karla Priscila Ferro their valuable technical assistance.















### **Funding details**

This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq/MCT), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Fundação de Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Cancer Research UK (AJR).









## References

1. Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. *J Gen Physiol* 1927; 8:519-30.
2. Fendt SM, Bell EL, Keibler MA, Olenchock BA, Mayers JR, Wasylenko TM, et al. Reductive glutamine metabolism is a function of the alpha-ketoglutarate to citrate ratio in cells. *Nat Commun* 2013; 4:2236.
3. Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. *Nat Rev Cancer* 2016; 16:619-34.
4. Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine Metabolism in Cancer: Understanding the Heterogeneity. *Trends Cancer* 2017; 3:169-80.
5. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. *Cancer Cell* 2010; 18:207-19.
6. Wynn ML, Yates JA, Evans CR, Van Wassenhove LD, Wu ZF, Bridges S, et al. RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells. *J Biol Chem* 2016; 291:13715-29.
7. Haikala HM, Marques E, Turunen M, Klefstrom J. Myc requires RhoA/SRF to reprogram glutamine metabolism. *Small GTPases* 2018:1-9.
8. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. *Nature* 2000; 406:532-5.
9. Ridley AJ. RhoA, RhoB and RhoC have different roles in cancer cell migration. *J Microsc* 2013; 251:242-9.
10. Vanni C, Ognibene M, Finetti F, Mancini P, Cabodi S, Segalerba D, et al. Dbl oncogene expression in MCF-10 A epithelial cells disrupts mammary acinar architecture, induces EMT and angiogenic factor secretion. *Cell Cycle* 2015; 14:1426-37.
11. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). *Invest Urol* 1979; 17:16-23.
12. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. *Cancer Res* 1983; 43:1809-18.
13. Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP, et al. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. *Cancer Res* 2004; 64:5311-21.
14. Dozmorov MG, Hurst RE, Culkin DJ, Kropp BP, Frank MB, Osban J, et al. Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. *Prostate* 2009; 69:1077-90.
15. Zacharias NM, McCullough C, Shanmugavelandy S, Lee J, Lee Y, Dutta P, et al. Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer. *Sci Rep* 2017; 7:16159.
16. Fu YM, Lin H, Liu X, Fang W, Meadows GG. Cell death of prostate cancer cells by specific amino acid restriction depends on alterations of glucose metabolism. *J Cell Physiol* 2010; 224:491-500.
17. Villalonga P, Ridley AJ. Rho GTPases and cell cycle control. *Growth Factors* 2006; 24:159-64.
18. Lazarini M, Traina F, Machado-Neto JA, Barcellos KS, Moreira YB, Brandao MM, et al. ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells. *Biochim Biophys Acta* 2013; 1832:365-74.
19. Vega FM, Fruhwirth G, Ng T, Ridley AJ. RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. *J Cell Biol* 2011; 193:655-65.










20. Pille JY, Denoyelle C, Varet J, Bertrand JR, Soria J, Opolon P, et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. *Mol Ther* 2005; 11:267-74.
21. Xie S, Zhu M, Lv G, Zhang Q, Wang G. The role of RhoC in the proliferation and apoptosis of hepatocellular carcinoma cells. *Med Oncol* 2012; 29:1802-9.
22. Song Y, Wong C, Chang DD. Overexpression of wild-type RhoA produces growth arrest by disrupting actin cytoskeleton and microtubules. *J Cell Biochem* 2000; 80:229-40.
23. Lang S, Busch H, Boerries M, Brummer T, Timme S, Lassmann S, et al. Specific role of RhoC in tumor invasion and metastasis. *Oncotarget* 2017; 8:87364-78.
24. Chang RM, Pei L, Fang F, Xu JF, Yang H, Zuo CH, et al. YMO1 suppresses invasion and metastasis by inhibiting RhoC signaling and predicts favorable prognosis in hepatocellular carcinoma. *Oncotarget* 2016; 7:55585-600.
25. Tseliou M, Al-Qahtani A, Alarifi S, Alkahtani SH, Stournaras C, Sourvinos G. The Role of RhoA, RhoB and RhoC GTPases in Cell Morphology, Proliferation and Migration in Human Cytomegalovirus (HCMV) Infected Glioblastoma Cells. *Cell Physiol Biochem* 2016; 38:94-109.
26. Garcia-Mariscal A, Li H, Pedersen E, Peyrollier K, Ryan KM, Stanley A, et al. Loss of RhoA promotes skin tumor formation and invasion by upregulation of RhoB. *Oncogene* 2018; 37:847-60.
27. Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. *Nat Genet* 2014; 46:583-7.
28. Nagata Y, Kontani K, Enami T, Kataoka K, Ishii R, Totoki Y, et al. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. *Blood* 2016; 127:596-604.
29. Machado-Neto JA, Lazarini M, Favaro P, Franchi GC, Jr., Nowill AE, Saad ST, et al. ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. *Exp Cell Res* 2014; 324:137-45.
30. Kazmers NH, Ma SA, Yoshida T, Stern PH. Rho GTPase signaling and PTH 3-34, but not PTH 1-34, maintain the actin cytoskeleton and antagonize bisphosphonate effects in mouse osteoblastic MC3T3-E1 cells. *Bone* 2009; 45:52-60.





**A****B****C****D**



**A****B****D****C****E****G****I****F****H****J**